A Phase II Evaluation of Panitumumab and Gemcitabine as Treatment for Women With Recurrent Epithelial Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Aug 2015
At a glance
- Drugs Panitumumab (Primary) ; Gemcitabine
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms PanGem
- 24 Jun 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 22 Feb 2011 New trial record